Associated Papers
Genomic Ascertainment of CHEK2-Related Cancer Predisposition.
Kim SY et al.
Jama Network Open, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants.
Stubbins RJ et al.
Leukemia, 2025
Focal High-Grade Areas with a Tumor-in-Tumor Pattern: Another Feature of Pediatric DICER1-Associated Thyroid Carcinoma?
Schiavo Lena M et al.
Endocrine Pathology, 2025
A missense variant effect map for the human tumor-suppressor protein CHK2.
Gebbia M et al.
American Journal of Human Genetics, 2024
Endometrioid ovarian carcinoma landscape: pathological and molecular characterization.
de Nonneville A et al.
Molecular Oncology, 2024
Genomic ascertainment of CHEK2-related cancer predisposition.
Kim SY et al.
Medrxiv : the Preprint Server for Health Sciences, 2024
Comprehensive analysis of the functional impact of single nucleotide variants of human CHEK2.
McCarthy-Leo CE et al.
Plos Genetics, 2024
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.
Wei Y et al.
Molecular Oncology, 2023
ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk.
Stolarova L et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Targeted deep sequencing reveals genomic alterations of actinic keratosis/cutaneous squamous cell carcinoma in situ and cutaneous squamous cell carcinoma.
Kim YS et al.
Experimental Dermatology, 2023
Identification of potential driver mutations in glioblastoma using machine learning.
Pandey M et al.
Briefings in Bioinformatics, 2022
Mutation profiles in circulating cell-free DNA predict acquired resistance to olaparib in high-grade serous ovarian carcinoma.
Hu D et al.
Cancer Science, 2022
Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
Boonen RACM et al.
Cancer Research, 2022
Identification of CHEK2 germline mutations in BRCA1/2 and PALB2 negative breast and ovarian cancer patients.
Aksoy F et al.
Human Heredity, 2022
Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype.
Ibragimova MK et al.
Cancers, 2021
Recurrent Germline Mutations of CHEK2 as a New Susceptibility Gene in Patients with Pheochromocytomas and Paragangliomas.
Gao Y et al.
International Journal of Endocrinology, 2021
Screening of germline mutations in young Rwandan patients with breast cancers.
Uyisenga JP et al.
Molecular Genetics & Genomic Medicine, 2020
Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians.
Yadav S et al.
Oncogene, 2020
Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer.
Ansari N et al.
Laboratory Medicine, 2019
UCHL1 loss alters the cell-cycle in metastatic pancreatic neuroendocrine tumors.
Finnerty BM et al.
Endocrine-related Cancer, 2019
[Hereditary predisposition to breast cancer (1): genetics].
Cohen-Haguenauer O
Medecine Sciences : M/s, 2019
Computational analysis of high-risk SNPs in human CHK2 gene responsible for hereditary breast cancer: A functional and structural impact.
Badgujar NV et al.
Plos One, 2019
Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells.
Luo L et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 2018
Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
Fan Z et al.
Breast Cancer Research and Treatment, 2018
Genomic analysis reveals frequent TRAF7 mutations in intraneural perineuriomas.
Klein CJ et al.
Annals of Neurology, 2017
KinView: a visual comparative sequence analysis tool for integrated kinome research.
McSkimming DI et al.
Molecular Biosystems, 2016
Prevalence of the CHEK2 R95* germline mutation.
Knappskog S et al.
Hereditary Cancer in Clinical Practice, 2016
A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk.
Wang N et al.
Oncogene, 2015